Neudesin regulates dendritic cell function and antitumor CD8⁺ T cell immunity

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Dendritic cells (DCs) are crucial for effective anti-tumor T-cell responses, particularly in immune checkpoint inhibitor (ICI) therapies.
• The secreted protein neudesin has been identified as a suppressor of DC function and is highly expressed in various human cancers.

Purpose of the Study:

• To investigate the role of neudesin in cancer immunity and its impact on immunotherapy outcomes.
• To explore neudesin as a potential therapeutic target for enhancing anti-cancer immune responses.

Main Methods:

• Analysis of cancer-related databases for neudesin expression in melanoma patients.
• In vivo studies using mouse tumor models with neudesin deficiency.
• Assessment of immune cell infiltration (DCs, CD8+ T cells) and vaccine efficacy.

Main Results:

• Low neudesin expression in melanoma patients correlated with increased DC and CD8+ T cell infiltration and improved ICI therapy outcomes.
• Neudesin deficiency in mouse models led to delayed tumor growth and increased proportions of conventional Type 1 DCs (cDC1s) and tumor-specific CD8+ T cells.
• A vaccine using neudesin-deficient cDC1s demonstrated enhanced systemic anti-tumor immunity compared to wild-type cDC1 vaccines.

Conclusions:

• Neudesin plays a significant role in suppressing cancer immunity.
• Targeting neudesin presents a promising novel strategy for improving cancer immunotherapy.
• Reduced neudesin expression enhances the efficacy of dendritic cell-based anti-cancer vaccines.